Walgreens Boots Alliance Inc
- Walgreens Boots Alliance increased 0.1% to $25.60 after the pharmacy operator reported fiscal first-quarter earnings and revenues that were ahead of market expectations.
Revenue in the quarter increased by 10%. $36.7 billion from $33.4 billion, net loss attributable to shareholders shrank to $67 million from $3.7 billion, and diluted loss per share declined to 8 cents from $4.431 a year ago.
In the quarter, operating loss improved to $39 million compared to an operating loss of $6.2 billion in the year-ago quarter because of lapping the $6.5 billion pre-tax charge for opioid-related claims and litigation recorded in the year-ago quarter.
Adjusted operating income was $687 million, a decrease of 33% on a constant currency basis reflecting softer U.S. retail market trends, partly offset by improved profitability in the U.S. market and growth in international operations.
The U.S. retail pharmacy segment sales increased 6.4% to $28.9 billion, and comparable sales increased 8.1% from the year-ago quarter, respectively.
Comparable prescriptions filled in the quarter increased 1.3% from the year-ago quarter, while excluding immunizations, they increased 1.8%, impacted by lower market growth due to a weaker flu and respiratory season and Medicaid redeterminations.
Total prescriptions filled in the quarter, including immunizations adjusted to 30-day equivalents, were 311.6 million, steady compared to the quarter a year ago.
The retailer cut the quarterly dividend by 48% to 25 cents from 48 cents a year ago to strengthen its balance sheet and improve its cash position.
The company reiterated its fiscal 2024 adjusted earnings per share estimate of between $3.20 and $3.50.
Jan 4, 2024 - Walgreens Boots Alliance increased 0.8% to $22.89 after the retail pharmacy chain reported mixed quarterly results and forecasted weak annual earnings growth outlook.
Revenue in the fiscal fourth quarter ending in August increased to $35.4 billion from $32.4 billion and net loss shrank from $180 million from $415 million and diluted loss per share fell to 21 cents from 48 cents a year ago.
Fiscal 2023 sales increased 4.8% to $139.1 billion from $132.7 billion and net income swung to a loss of $3.1 billion from $4.3 billion a year ago.
Earnings in the year were impacted by the sharp decline in Covid-19 testing and vaccine volumes.
The pharmacy retail chain guided fiscal 2024 sales in the range between $141 billion and $145 billion and adjusted earnings per share between $3.20 and $3.50.
Oct 12, 2023 - Walgreens Boots Alliance Inc dropped 8.9% to $28.97 after the pharmacy retail chain reported lower-than-expected fiscal third quarter earnings.
The company also lowered its full-year earnings outlook.
Revenue in the fiscal third quarter ending in May increased to $35.2 billion from $32.6 billion and net earnings attributable to shareholders plunged to $118 million from $289 million and diluted earnings per share dropped to 14 cents from 33 cents a year ago.
For the full fiscal year 2023, Walgreens Boots Alliance now expects adjusted earnings per share between $4.00 and $4.05 from the previous estimate of $4.45 to $4.65, reflecting challenging consumer and macroeconomic conditions, and lower COVID-19 vaccine and testing volumes.
For the fiscal year 2024, the company is forecasting "low- to mid-single digit adjusted operating income growth, with the U.S. Healthcare and U.S. Retail Pharmacy performance more than offsetting headwinds from lower sale and leaseback program benefits, lower COVID-19 contribution, and the sale of holdings in AmerisourceBergen."
Jun 27, 2023 - Walgreens Boots Alliance Inc, the pharmacy operator, reported better-than-expected fiscal second quarter earnings.
Sales in the fiscal second quarter ending in February increased 3.3% to $34.8 billion from $33.7 billion and net income fell to $703 million from $883 million and diluted earnings per share declined to 81 cents from $1.02 a year ago.
The company retained its full-year adjusted earnings per share outlook between $4.45 and $4.65 a share, reflecting acceleration in business in February.
Mar 28, 2023 - Walgreens said fiscal first quarter revenue eased 1.5% to $33.3 billion and swung to a net loss of $3.72 billion or $4.31 a share on $5.2 billion pre-tax charge related to opioid settlement.
Jan 5, 2023
| Year | Nov | Feb | May | Aug | Annual | |
|---|---|---|---|---|---|---|
| 2023 | 0.81 | 0.14 | -0.21 | -0.08 | -3.57 | |
| 2022 | 1.02 | 0.33 | -0.47 | -4.31 | 5.01 | |
| 2021 | 1.19 | 1.38 | 0.72 | 4.13 | 2.93 | |
| 2020 | 1.07 | -1.95 | 0.45 | -0.36 | 0.52 | |
| 2019 | 1.64 | 1.47 | 1.43 | - | 4.31 | |
| 2018 | 1.73 | 1.53 | 1.48 | 1.46 | 5.05 | |
| 2017 | 1.36 | 1.33 | 1.31 | 1.28 | 5.28 | |
| 2016 | 1.31 | 2.88 | 1.07 | 1.10 | 3.48 | |
| 2015 | 1.18 | 1.02 | 0.88 | 1.03 | 4.11 | |
| 2014 | 0.89 | 0.74 | 0.74 | -0.20 | 2 | |
| 2013 | 0.72 | 0.79 | 0.65 | 0.80 | 2.67 | |
| 2012 | 0.43 | 0.78 | 0.62 | 0.39 | 2.42 | |
| 2011 | 0.63 | 0.80 | 0.65 | 0.87 | 2.94 | |
| 2010 | 0.62 | 0.68 | 0.47 | 0.48 | 2.12 | |
| 2009 | 0.49 | 0.65 | 0.53 | 0.43 | 2.02 | |
| 2008 | 0.41 | 0.69 | 0.58 | 0.44 | 2.17 | |
| 2007 | 0.46 | 0.65 | 0.56 | 0.39 | 2.03 | |
| 2006 | 0.43 | 0.51 | 0.46 | 0.41 | 1.72 | |
| 2005 | 0.34 | 0.48 | 0.40 | 0.32 | 1.52 |